Search

everythinglearnresearchcommunity

for

Search:↓

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Deleting the Trf1 protein in mice is safe and may help prevent cancer without major side effects.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

CXCR2 in skin cells promotes tumor growth.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

RIPK1 inhibitors might help prevent alopecia areata.

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Tofacitinib treatment for hair loss may worsen acne.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.